The present invention describes the use of a 5HT3-antagonist, in combination with neostigmine, to facilitate the treatment of a patient suffering from myasthenia gravis or other myasthenic syndromes by providing a therapeutically effective neostigmine bromide or methylsulfate daily dose that attenuates or even abrogates the dose-limiting gastrointestinal adverse effects of neostigmine.本發明描述5HT3拮抗劑與新斯的明(neostigmine)組合之用途，其藉由提供減弱或甚至消除新斯的明之劑量限制性腸胃不良作用的治療學上有效之溴化新斯的明或甲硫酸新斯的明日劑量，以便輔助治療罹患重症肌無力或其他肌無力症候群之患者。
